Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are types of cancer in which too many white blood cells (B-cells) are produced, these cells build up in the lymph nodes, blood, and bone marrow. As these cells develop abnormally, they are unable to function, fight infection and reduce the production of healthy blood cells. These diseases are chronic and develop slowly. Relapsed cancer is when the cancer returns after treatment, whereas refractory is when the cancer does not respond to treatment. Treatment is complex and depends on several factors, including the extent of disease, previous treatment, patient’s age, symptoms, and general state of health. There is an unmet need to develop more effective, and better tolerated treatment options to improve long-term outcomes for patients.